Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

PJ DiPentino felt uneasy about his local oncologist’s plan. DiPentino’s bladder cancer had returned in a lymph node, and the ...

Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...